Activities
Contacts
Business Development |
Overview
On of Cellectis' foremost assets is its intellectual property portfolio. The Institut Pasteur patent families covering the use of Homologous recombination and meganuclease-type endonucleases for inducing DNA recombination formed the Platform upon which Cellectis was initially founded.